Gene expression with covalently modified polynucleotides

• US 7,491,538 B2
• Filed: 07/26/2005
• Issued: 02/17/2009
• Est. Priority Date: 08/02/1999
• Status: Active Grant

• Current Assignee: Mirus Bio LLC
• Original Assignee: Mirus Bio LLC
• Inventors: Slattum, Paul M., Hagstrom, James E., Wolff, Jon A., Budker, Vladimir G.
• Primary Examiner(s): Ketter; James S
• Application Number:
  US11/189,321
• Publication Number:
  US 20050272154A1
• Time in Patent Office: 1,302 Days
• Field of Search: None
• US Class Current: 435/458
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

A process and compound wherein nucleic acids can be modified with a host of molecules and maintain their ability to be expressed. A modifying chemical attachment of polyions to polynucleotides can be used to facilitate the change of tertiary structure of the nucleic acid and in some cases condensation of nucleic acids into smaller, charged particles useful in delivering the nucleic acid to a cell.

Claims

1. A complex for delivering a nucleic acid to a cell, comprising:

said nucleic acid modified at the N7 positions of guanines in the nucleic acid with a plurality of alkylating agents selected from the list consisting of;

a) compounds having a group containing three or more positively charge groups and a net positive charge linked to a mustard or three-membered ring nucleic acid reactive group;

b) compounds having three mustard nucleic acid reactive groups; and

wherein reaction with the nucleic acid crosslinks the nucleic acid; and

,

c) compounds having a sulfhydryl or disulfide group and a mustard or three-membered ring nucleic acid reactive group wherein the sulfhydryl or disulfide groups are oxidized or exchanged to form disulfide bonds between pairs of compounds attached to the nucleic acid, thereby crosslinking the nucleic acid;

wherein said modification compacts, reduces the volume of, or reduces the hydrodynamic radius of the nucleic acid when compared to the unmodified nucleic acid.

2. The complex of claim 1 wherein the change in tertiary structure results in a retention of greater than 40% expression of an expressible sequence present in the nucleic acid when compared to the expressible sequence in the unmodified nucleic acid.

3. The complex of claim 1 further comprising a targeting ligand attached to the nucleic acid.

4. The complex of claim 1 wherein the mustard is selected from the group consisting of a nitrogen mustard and a sulfur mustard.

5. The complex of claim 1 wherein the 3-membered ring system is selected from the group consisting of aziridines, oxiranes, cyclopropyls, and episulfides.

6. The complex of claim 4 wherein the nitrogen mustard consists of an 4-[(2-chloroethyl)-methylamino]-benzylamine derivative.

7. The complex of claim 5 wherein the 3-membered ring system consists of a cyclopropa-pyrrolo-indol moiety.

11. The complex of claim 1 wherein the nucleic acid is crosslinked.

12. The complex of claim 11 wherein the nucleic acid is crosslinked via a disulfide bond.

13. The complex of claim 1 wherein the compound is positively charged.

14. The complex of claim 13 wherein the compound contains a plurality of positive charges.

8. A complex for delivering a nucleic acid to a cell, comprising:

said nucleic acid modified at the N7 positions of guanines in the nucleic acid via formation of Lewis acid;

Lewis base complexes with a plurality of modifying agents selected from the group consisting of;

a) compounds having a group containing three or more positively charge groups and a net positive charge linked to a Lewis acid, wherein the Lewis acid is not a hydrogen; and

,

b) compounds having a sulfhydryl or disulfide group linked to a Lewis acid, wherein the Lewis acid is not a hydrogen, and wherein the sulfydryl or disulfide groups are oxidized or exchanged to form a disulfide bond between pairs of compounds attached to the nucleic acid, thereby crossliniking the nucleic acid;

wherein said modification compacts, reduces the volume of, or reduces the hydrodynamic radius of the nucleic acid when compared to the unmodified nucleic acid.

9. The complex of claim 8 wherein the Lewis acid is a transition metal.

10. The complex of claim 9 wherein the Lewis acid is platinum.